1. Stability, Responsiveness, and Reproducibility of a Visual Analog Scale for Treatment Satisfaction in Migraine.
- Author
-
Lucas, Christian, Romatet, Sophie, Mekiès, Claude, Allaf, Bashar, and Lantéri-Minet, Michel
- Subjects
- *
SEROTONIN agonists , *PATIENT satisfaction , *LONGITUDINAL method , *RESEARCH methodology , *MIGRAINE , *PROBABILITY theory , *RESEARCH funding , *SCALES (Weighing instruments) , *STATISTICS , *DATA analysis , *VISUAL analog scale , *RESEARCH methodology evaluation , *DIARY (Literary form) , *DESCRIPTIVE statistics , *THERAPEUTICS - Abstract
Objectives.- To evaluate the stability, responsiveness, and reproducibility of a simple visual analog scale (VAS). Background.- In order to help physicians in the management of migraine in everyday general practice and assess whether the treatments that they are currently prescribing are actually effective, a VAS of treatment satisfaction with acute migraine treatments has been developed. Methods.- The study used an open-label, multicenter, prospective design. Adult patients fulfilling diagnostic criteria for migraine and who consulted a participating hospital or community neurology clinic were eligible. At inclusion, patients rated their satisfaction with their current treatment on the VAS. Those scoring 7-10 (satisfied) on the VAS were allocated to the VASCO cohort, and those scoring 0-4 (dissatisfied) were switched to almotriptan and allocated to the ALMO cohort. Patients scoring between 4 and 7 were assigned to 1 or other cohort at the physician's discretion. The VAS was re-administered at home the next day and also after the treatment of 3 further headaches, both at home and at a follow-up visit. Results.- Ninety-eight patients in the VASCO cohort and 102 in the ALMO cohort were analyzed. Stability was evaluated in the VASCO cohort: 55/98 patients initially satisfied with treatment remained so at study end, whereas 7/98 became dissatisfied. Responsiveness of the VAS to a change in treatment was evaluated in the ALMO cohort: 64/102 patients moved to a higher treatment satisfaction category, whereas 6/102 moved to a lower one. Reproducibility of the VAS was determined in 4 settings (both at the inclusion visit and at study closure in both cohorts). In each setting, VAS scores were compared between consultation and at-home ratings. In 3 of the 4 settings (both measures in the ALMO cohort and at study closure in the VASCO cohort), good agreement was observed between the 2 ratings (κ = 0.62-0.69). At inclusion in the VASCO cohort, agreement was only fair (κ = 0.33). Conclusions.- The VAS scale described here is a responsive and easy-to-use tool for evaluating treatment satisfaction and for monitoring changes to treatment if these are required. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF